Jefferies Group’s Pacira BioSciences PCRX Stock Holding History

Jefferies Group’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-15,000	Closed	-$875K	–	1863
2022 Q2	$875K	Buy	+15,000	New	+$983K	0.01%	837
2021 Q4	–	Sell	-50,000	Closed	-$2.8M	–	1906
2021 Q3	$2.8M	Buy	+50,000	New	+$2.88M	0.02%	630
2021 Q2	–	Sell	-27,000	Closed	-$1.89M	–	1919
2021 Q1	$1.89M	Sell	27,000 -45,000	-63%	-$3.21M	0.02%	706
2020 Q4	$4.31M	Buy	+72,000	New	+$4.22M	0.03%	460
2020 Q3	–	Sell	-12,600	Closed	-$661	–	1498
2020 Q2	$661	Sell	12,600 -87,000	-87%	-$3.64M	0.01%	847
2020 Q1	$3.34M	Buy	+99,600	New	+$4.14M	0.04%	459
2019 Q4	–	Sell	-10,600	Closed	-$404K	–	2878
2019 Q3	$404K	Buy	10,600 +600	+6%	+$23.9K	﹤0.01%	1994
2019 Q2	$435K	Buy	+10,000	New	+$425K	﹤0.01%	1733
2019 Q1	–	Sell	-12,500	Closed	-$538K	–	2551
2018 Q4	$538K	Sell	12,500 -44,500	-78%	-$2.08M	﹤0.01%	1434
2018 Q3	$2.8M	Buy	57,000 +39,100	+218%	+$1.69M	0.02%	818
2018 Q2	$574K	Buy	+17,900	New	+$618K	﹤0.01%	1525
2016 Q2	–	Sell	-2,000	Closed	-$106K	–	2369
2016 Q1	$106K	Buy	+2,000	New	+$117K	﹤0.01%	1964
2015 Q2	–	Sell	-60,100	Closed	-$5.34M	–	3450
2015 Q1	$5.34M	Buy	+60,100	New	+$6.1M	0.03%	404

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Jefferies Group's PCRX Position: Q3 2022 in Review

Jefferies Group increased its Pacira BioSciences (PCRX) stake by 299% in Q3 2022, buying an estimated $1.25M and bringing the position to 29,954 shares worth $1.59M. The position accounts for 0.01% of the portfolio, ranked #678.

Jefferies Group first reported a position in PCRX in Q2 2013 and has held it in 27 quarters since. The position peaked at $6.55M in Q1 2020. 273 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

Jefferies Group held 29,954 shares of Pacira BioSciences worth $1.59M as of Q3 2022.
Jefferies Group bought 22,454 Pacira BioSciences shares in Q3 2022, an estimated $1.25M.
Pacira BioSciences made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #678 holding.
Jefferies Group first reported a position in Pacira BioSciences in Q2 2013 and has held it in 27 quarters since.
Jefferies Group's Pacira BioSciences position peaked at $6.55M in Q1 2020.
273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.